Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder. In ALS patients, the gradual death of nerve cells in the brain and spinal cord that control muscles can result in weakened muscles throughout the body. As the disease progresses and more muscles are affected, getting around and accomplishing…

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder. In patients with ALS the gradual death of nerve cells in the brain and spinal cord that control muscles can result in the progressive weakening of muscles throughout the body. The severity of symptoms experienced by patients with ALS can change…

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder in which the gradual death of nerve cells in the brain results in a progressive weakening of muscles throughout the body. While the symptoms of ALS often vary among patients, breathing problems will at some point confront all of them. When the muscles involved in breathing weaken,…

Dysport (abobotulinumtoxinA), made by Ipsen Biopharmaceuticals, is an injectable drug to treat spasticity in adults. The U.S. Food and Drug Administration (FDA) first approved its use in July 2015 to treat upper limb spasticity, but in June 2017, the FDA extended approval for Dysport to treat lower limb spasticity as well.

Amyotrophic lateral sclerosis (ALS) (also known as Lou Gehrig’s disease) often is mistaken for multiple sclerosis (MS). In fact, they share similar symptoms and features, such as scarring around the nerves (sclerosis), causing muscle spasms, difficulty in walking, and fatigue. ALS characteristics ALS is a rapidly progressing and…